WENA
NASDAQANEW MEDICAL INC.
News25/Ratings0
Latest news
25 items- SECSEC Form EFFECT filed by ANEW MEDICAL INC.EFFECT - ANEW Medical, Inc. (0001907223) (Filer)
- PRANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company's patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company's patent protected secr
- SECSEC Form S-1 filed by ANEW MEDICAL INC.S-1 - ANEW Medical, Inc. (0001907223) (Filer)
- PRHealthy Longevity is One of Key Development Goals of ANEW's Novel Gene TherapyNEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as "the anti-aging gene." It is named after the
- SECANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update8-K - ANEW Medical, Inc. (0001907223) (Filer)
- PRANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial FlexibilityNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW's balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW's balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The avera
- SECANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update8-K - ANEW Medical, Inc. (0001907223) (Filer)
- SECANEW MEDICAL INC. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ANEW Medical, Inc. (0001907223) (Filer)
- PRANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th
- SECSEC Form 10-Q filed by ANEW MEDICAL INC.10-Q - ANEW Medical, Inc. (0001907223) (Filer)
- PRANEW MEDICAL, INC. Appoints New CFONEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope
- PRANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related DiseasesNEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 ("the 268 patent") covering the secreted RNA splice variant of the human Klotho gene, referred to as "s-KL", for the treatment of cognitive and neurodegenerative diseases. The human Klotho gene, sometimes referred to as the "anti-aging" gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property ("IP") protec
- SECSEC Form NT 10-Q filed by ANEW MEDICAL INC.NT 10-Q - ANEW Medical, Inc. (0001907223) (Filer)
- PRANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding PeptidesMelanocortin receptors on neurons in the brain control feeding and weight lossPatented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain. The neurobiology of overeating and obesity is well known, and the melanocortin-3 and melanocortin-4 receptors are definitively invol
- PRANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer's Disease and ALSPatents issued in mainland China protect the Company's novel secreted Klotho protein and Its gene delivery systemRecent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer's Disease and other neurodegenerative diseases NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer's disease, Parkins
- SECANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update8-K - ANEW Medical, Inc. (0001907223) (Filer)
- NEWSWhy VivoPower International Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketShares of VivoPower International PLC (NASDAQ:VVPR) rose sharply in today's pre-market trading after the company announced it secured an extension for a $34 million loan financing facility agreement. VivoPower International shares jumped 31.4% to $3.35 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Ampco-Pittsburgh Corporation (NYSE:AP) rose 72.6% to $1.32 in pre-market trading. Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares rose 40.4% to $0.9516 in pre-market trading after gaining 36% on Tuesday. NaaS Technology Inc. (NASDAQ:NAAS) gained 40% to $4.55 in pre-market trading after surging 68% on Tuesday. Soligenix, Inc. (NASDAQ:SNG
- NEWSWhy Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionShares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
- NEWSMarket-Moving News for July 9thSNGX: 142% | Soligenix shares are trading higher after the company announced interim results for extended HyBryte treatment in early-stage CTCL patients. WENA: 138% | Anew Medical shares are trading higher after the company announced plans to accelerate its Klotho gene therapy program for neurodegenerative disorders. JNVR: 87% | EXCLUSIVE: Janover shares are trading higher after the company announced that its AI loan advisor generated over 4,000 deals worth over $25 billion to date in 2024. Also, the company announced it facilitated nearly $10 million in funded loans this year.
- NEWSThis Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's DiseasesIn Tuesday’s pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders. What Happened: ANEW, a biopharmaceutical company that specializes in developing innovative therapies for neurological and age-related disorders, was trading at $2.460 at the time of writing, up from Monday’s close at $1.450, according to Benzinga Pro data. ANEW’s preliminary data indicates that maintaining high Klotho levels in the body could result in longer, healthier lives. Conversely, individuals with lower Klotho levels are more susceptible to neurodegenerative
- NEWSAnew Medical shares are trading higher after the company announced plans to accelerate its Klotho gene therapy program for neurodegenerative disorders.
- NEWSANEW MEDICAL Plans To Accelerate Its Patented Klotho Gene Therapy Program For Neurodegenerative Disorders.
- NEWSAnew Medical Advances Klotho Gene Therapy to Combat Neurodegenerative Disorders and Promote LongevityANEW MEDICAL, INC. (NASDAQ:WENA) (“ANEW”), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, announces plans to advance its recently patented Klotho gene therapy program for neurodegenerative disorders. ANEW has compelling initial data suggesting that maintaining elevated levels of Klotho in the body significantly contributes to longer, healthier lifespans. Conversely, the data reveals that individuals with depleted or lower-than-normal levels of Klotho are more susceptible to neurodegenerative disorders such as ALS, Alzheimer’s, and Parkinson’s Disease. ANEW will also investigate other age-related di
- PRANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder TreatmentsGenomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA) ("ANEW"), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, announces plans to advance its recently patented Klotho gene therapy program for neurodegenerative disorders. ANEW has compelling initial data suggesting that maintaining elevated levels of Klotho in the body significantly contributes to long
- INSIDERLarge owner Chardan Capital Markets Llc sold $725,162 worth of shares (342,136 units at $2.12) (SEC Form 4)4 - ANEW Medical, Inc. (0001907223) (Issuer)